Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Gap Up – What’s Next?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $13.07, but opened at $13.6050. Bayer Aktiengesellschaft shares last traded at $13.4951, with a volume of 633,632 shares changing hands.

Analysts Set New Price Targets

Several research firms recently commented on BAYRY. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Friday, May 8th. Jefferies Financial Group upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th. DZ Bank upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Finally, UBS Group raised Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a report on Monday, March 16th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Bayer Aktiengesellschaft presently has a consensus rating of “Moderate Buy”.

Get Bayer Aktiengesellschaft alerts:

Check Out Our Latest Stock Analysis on Bayer Aktiengesellschaft

Bayer Aktiengesellschaft Price Performance

The firm has a market cap of $53.90 billion, a P/E ratio of -21.43, a P/E/G ratio of 4.27 and a beta of 0.59. The company has a quick ratio of 0.70, a current ratio of 1.05 and a debt-to-equity ratio of 1.06. The business’s 50 day moving average is $10.99 and its two-hundred day moving average is $11.53.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last issued its quarterly earnings results on Tuesday, May 12th. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. The firm had revenue of $15.73 billion during the quarter, compared to the consensus estimate of $15.77 billion. Bayer Aktiengesellschaft had a positive return on equity of 17.61% and a negative net margin of 4.75%.Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, analysts anticipate that Bayer Aktiengesellschaft will post 1.25 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

(Get Free Report)

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.

Recommended Stories

• Five stocks we like better than Bayer Aktiengesellschaft
• The Quantum Bubble Is Real Enough to Take Seriously
• Why Wall Street Still Sees Massive Upside for AeroVironment Stock
• Why AppLovin’s CEO Is Selling While Quantum Insiders Are Buying
• Volkswagen’s 16-Year Low Masks a Massive Margin Engine

Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.